DAK-Gesundheit
Germany · 878 open tenders · 4,305 documented awards
Current tenders
Fidelity Guarantee Insurance
Deadline 21 Aug · 1 day left
Fidelity Guarantee Insurance
Deadline 21 Aug · 1 day left
Drywall work DAK-Gesundheit | Central office (Hamburg) + Academy (Bad Segeberg)
BELOW THRESHOLDDeadline 27 Aug · 7 days left
Framework Agreement Carpentry Work | Central Office (Hamburg) + Academy (Bad Segeberg)
BELOW THRESHOLDDeadline 31 Aug · 11 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for active substance allergen extract various origins (subcutaneous injections; V01AA02, V01AA03, V01AA05), for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Dasatinib (excluding strength 100 mg in standard pack sizes N2 and N3, ATC L01EA02 for the period 01.11.24 - 31.10.26
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active substance lanreotide, ATC H01CB03 (OBO) for the period 01.11.2024 - 31.10.2025 (plus extension option 1x12 months)
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Cinacalcet (excluding strengths 30mg, 60mg, 90mg in standard pack size N3, ATC H05BX01 for the period 01.11.24-31.10.26
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a paragraph 8 SGB V for the active substance thalidomide, ATC L04AX02 (OBG) for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a Paragraph 8 SGB V for the active ingredient nadroparin, ATC B01AB06 (OBG) for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Nadroparin, ATC B01AB06 (OBG) for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient lanreotide, ATC H01CB03 (OBO) for the period 01.11.2024 - 31.10.2025 (plus extension option 1x12 months)
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient tapentadol (excluding strength 25 mg in standard size N3), (OBG) ATC N02AX06 for the period 01.11.24 - 31.10.26
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient Interferon beta-1a (excl. for subcutaneous use), ATC L03AB07 for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Dasatinib (excluding strength 100 mg in standard pack sizes N2 and N3, ATC L01EA02 for the period 01.11.24 - 31.10.26
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Thalidomide, ATC L04AX02 (OBG) for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active ingredient Interferon beta-1a (excluding subcutaneous application), ATC L03AB07 for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient minoxidil, ATC C02DC01 (OBG) for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient minoxidil, ATC C02DC01 (OBG) for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient tapentadol (excluding strength 25 mg in standard pack size N3), (OBG) ATC N02AX06 for the period 01.11.24 - 31.10.26
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient allergen extract of various origins (subcutaneous injections; V01AA02, V01AA03, V01AA05), for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Cinacalcet (excluding strengths 30mg, 60mg, 90mg in standard pack size N3, ATC H05BX01 for the period 01.11.24-31.10.26
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Timolol + Brinzolamid, ATC S01ED67 (OBG) for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Germany – Pharmaceuticals – Conclusion of a non-exclusive discount agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Timolol + Brinzolamide, ATC S01ED67 (OBG) for the period 01.11.2024 - 31.10.2026
1 €Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive discount agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Nadroparin, ATC B01AB06 (OBG) for the period 01.11.2024 - 31.10.2026
Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient Cinacalcet (excluding strengths 30mg, 60mg, 90mg in standard pack size N3, ATC H05BX01 for the period 01.11.24-31.10.26
Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive rebate agreement pursuant to § 130a paragraph 8 SGB V for the active ingredient thalidomide, ATC L04AX02 (OBG) for the period 01.11.2024 - 31.10.2026
Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active substance Interferon beta-1a (excluding subcutaneous application), ATC L03AB07 for the period 01.11.2024 - 31.10.2026
Deadline 5 Sept · 16 days left
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for active ingredient allergen extract various origins (subcutaneous injections; V01AA02, V01AA03, V01AA05), for the period 01.11.2024 - 31.10.2026
Deadline 5 Sept · 16 days left
Reception Service for DAK-Gesundheit at the Hamburg Location (Nagelsweg)
Deadline 11 Sept · 22 days left
Purchasing rhythm
Awards per year — who knows the rhythm prepares before the notice appears.
2018260
2019344
2020261
2021310
2022346
2023459
2024949
20251,626
2026956
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Abacus Medicine A/S · Kopenhagen | 172 | 2022–2026 |
| kohlpharma GmbH · Merzig | 157 | 2022–2026 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 126 | 2022–2026 |
| CC Pharma GmbH · Densborn | 121 | 2022–2025 |
| Orifarm GmbH · Leverkusen | 113 | 2015–2025 |
| axicorp Pharma B.V. · EC Den Haag | 80 | 2022–2025 |
| ratiopharm GmbH | 75 | 2015–2026 |
| Originalis B.V. · Amsterdam | 74 | 2022–2025 |
| Zentiva Pharma GmbH · Frankfurt am Main | 56 | 2015–2025 |
| Hexal AG · Holzkirchen | 54 | 2013–2025 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.